Earnings results expected in 32 days
Summary
NVRO trading today higher at $5.84, an increase of 0% from yesterday's close, completing a monthly increase of 2.1% or $0.12. Over the past 12 months, NVRO stock gained 54.09%.
NVRO is not paying dividends to its shareholders.
The last earnings report, released on Mar 04, 2025, exceeded the consensus estimates by 0.02%. On average, the company has surpassed earnings expectations by 0.14%, based on the last three reports. The next scheduled earnings report is due on May 05, 2025.
Nevro Corp has completed 1 stock splits, with the recent split occurring on Nov 06, 2014.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track NVRO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
NVRO Chart
Nevro Corp Dividends
NVRO is not paying dividends to its shareholders.
Nevro Corp Earnings
| 5 May 2025 (32 Days) Date | | - Cons. EPS | - EPS |
| 4 Mar 2025 Date | | - Cons. EPS | - EPS |
| 19 Feb 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
NVRO is not paying dividends to its shareholders.
| 5 May 2025 (32 Days) Date | | - Cons. EPS | - EPS |
| 4 Mar 2025 Date | | - Cons. EPS | - EPS |
| 19 Feb 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
Nevro Corp (NVRO) FAQ
What is the stock price today?
The current price is $5.84.
On which exchange is it traded?
Nevro Corp is listed on NYSE.
What is its stock symbol?
The ticker symbol is NVRO.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 442.74M.
What is the earnings per share?
The EPS is 0.
When is the next earnings date?
The next earnings report will release on May 05, 2025.
Has Nevro Corp ever had a stock split?
Nevro Corp had 1 splits and the recent split was on Nov 06, 2014.
Nevro Corp Profile
| Medical Devices Industry | Healthcare Sector | Mr. Roderick H. MacLeod CEO | NYSE Exchange | US64157F1030 ISIN |
| US Country | 1,215 Employees | - Last Dividend | 6 Nov 2014 Last Split | 6 Nov 2014 IPO Date |
Overview
Nevro Corp. is a distinguished entity within the medical device industry, focusing on the development and provision of innovative solutions for individuals suffering from chronic pain, both in the United States and internationally. Established in 2006 and having its headquarters in Redwood City, California, Nevro Corp. has set itself apart by offering advanced therapeutic products designed to alleviate chronic back and leg pain without the need for paresthesia. The company leverages its direct sales force alongside a network of sales agents and independent distributors to market its products, ensuring a wide reach to patients in need of their groundbreaking therapies.
Products and Services
Nevro Corp. offers a comprehensive range of products within its HFX spinal cord stimulation (SCS) platform and beyond, catering to the varied needs of patients suffering from chronic pain:
- Senza SCS Implantable Pulse Generator (IPG) System: A cornerstone of Nevro Corp.'s offering, this neuromodulation system employs 10 kHz therapy to treat chronic back and leg pain without inducing paresthesia. The system is evidence-based, highlighting its effectiveness and reliability.
- Senza II and Senza Omnia SCS IPG Systems: Building on the foundation laid by the original Senza system, these iterations offer enhanced features and flexibility, providing patients and healthcare professionals with additional options to tailor the treatment to individual needs.
- Senza HFX iQ Platform: This platform represents a leap forward in patient-centered care, incorporating the HFX iQ implantable pulse generator, the HFX trial stimulator, and the HFX iQ patient remote. It is complemented by the HFX App, which allows for seamless patient control and wireless trialing, further personalizing the pain management experience.
- Sacroiliac Joint Fusion Devices: Nevro Corp. extends its innovative approach to pain management to the sacroiliac joint, offering devices under the NevroV1, NevroFix, and NevroPro brands. These devices are designed to provide relief for patients with pain originating from the sacroiliac joint.
- Surpass Surgical and Percutaneous Leads: Completing its portfolio, Nevro Corp. provides advanced surgical and percutaneous leads, essential components for the effective delivery of neuromodulation therapy. These leads are designed to be both durable and flexible, meeting the high standards required for chronic pain treatments.
Contact Information
Address: 1800 Bridge Parkway, Redwood City, CA, United States, 94065
Phone: 650 251 0005
Website: https://nevro.com
2025 © Marketlog. All Rights Reserved.
